Clinical Fellow in Pediatrics, Boston Children's Hospital
Pediatric Hematology & Oncology
Dr. Vijay G. Sankaran, MD
|
|
Give Review
Doctor Vijay G. Sankaran, MD practices Pediatric Hematology & Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. Vijay G. Sankaran, MD has written publications. He has 38 publications published with PubMed. The lastest paper is: 'Society for Pediatric Research 2015 Young Investigator Award: Genetics of human hematopoiesis-What patients can teach us about blood cell production.'
Publications
- Society for Pediatric Research 2015 Young Investigator Award: Genetics of human hematopoiesis-What patients can teach us about blood cell production.
- Genome-wide association study follow-up identifies cyclin A2 as a regulator of the transition through cytokinesis during terminal erythropoiesis.
- Altered chromatin occupancy of master regulators underlies evolutionary divergence in the transcriptional landscape of erythroid differentiation.
- Altered translation of GATA1 in Diamond-Blackfan anemia.
- Transcriptional divergence and conservation of human and mouse erythropoiesis.
- Applications of high-throughput DNA sequencing to benign hematology.
- Stimulating erythropoiesis in neonates.
- Genome-wide association studies of hematologic phenotypes: a window into human hematopoiesis.
- The Switch from Fetal to Adult Hemoglobin.
- MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment.
- Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number.
- Fetal hemoglobin levels and morbidity in untransfused patients with ?-thalassemia intermedia.
- Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing.
- A functional element necessary for fetal hemoglobin silencing.
- Persistence of Fetal Hemoglobin Expression in an Older Child with Trisomy 13.
- Heterozygous disruption of human SOX6 is insufficient to impair erythropoiesis or silencing of fetal hemoglobin.
- Erythropoietin couples erythropoiesis, B lymphopoiesis, and bone homeostasis within the bone marrow microenvironment.
- Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
- MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13.
- Targeted therapeutic strategies for fetal hemoglobin induction.
- Reversing the hemoglobin switch.
- Thalassemia: an overview of 50 years of clinical research.
- Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation.
- Modifier genes in Mendelian disorders: the example of hemoglobin disorders.
- Traumatic bleeding of spinal angiolipoma presenting with subacute paraparesis--a case report and histopathological aspects.
- Hemoglobin disorders in the developing world: a perspective from Sri Lanka.
- Transcriptional silencing of fetal hemoglobin by BCL11A.
- Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.
- Advances in the understanding of haemoglobin switching.
- Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome.
- Developmental and species-divergent globin switching are driven by BCL11A.
- Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.
- Rb and hematopoiesis: stem cells to anemia.
- DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.
- Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.
- Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis.
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.
Schools
Harvard Medical School
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Boston Children's Hospital -
Harvard Medical School
Hospital
-
Boston Children's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. David A. Sweetser, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Nicolas V. Currier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Snaman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey Rubens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suneet Agarwal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emma M. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nmazuo W. Ozuah, MD |
|
|
Dr. Jeremy W. Rupon, MD
This Doctor is OpenDoctor Recommended.
|